Business
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal Q2 2027 BURLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today reported its financial results for its fiscal year e
About this update from Neuphoria Therapeutics Inc.
[{"type":"image","alt":"Neuphoria Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Neuphoria Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":134,"url":"https://media.zenfs.com/en/globenewswire.com/ebf32c6b9691a7e95d55714797b59361"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mnUSgCG0WTU8RlTRZzCzeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ebf32c6b9691a7e95d55714797b59361","width":300,"height":134}},"lazy":false},{"type":"text","content":"Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025","length":165,"tagName":"p"},{"type":"text","content":"Cash runway extended through fiscal Q2 2027","length":43,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today reported its financial results for its fiscal year ended June 30, 2025, and provided recent business updates.","length":347,"tagName":"p"},{"type":"text","content":"“It is an exciting time for Neuphoria as we rapidly approach topline data from our AFFIRM-1 Phase 3 study of BNC-210 in social anxiety disorder, which is anticipated early in the fourth quarter of this year,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Neuphoria. “BNC-210 is supported by a robust body of clinical data, demonstrating clinically meaningful effects across multiple stress and anxiety indications. These data, along with its differentiated safety profile, give us confidence in BNC-210 as a potentially transformative treatment for patients struggling with SAD.”","length":596,"tagName":"p"},{"type":"text","content":"Clinical Program Highlights","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The LPLV milestone has been achieved in the AFFIRM-1 Phase 3 trial evaluating BNC-210 as a first-in-class, acute, “as needed” treatment for SAD. Topline data are anticipated in early fourth quarter 2025.","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Start-up activities continue for the SYMPHONY Phase 2b/3 trial in...